Breaking Down Mereo BioPharma Group plc (MREO) Financial Health: Key Insights for Investors

Breaking Down Mereo BioPharma Group plc (MREO) Financial Health: Key Insights for Investors

GB | Healthcare | Biotechnology | NASDAQ

Mereo BioPharma Group plc (MREO) Bundle

Get Full Bundle:
$12 $7
$12 $7
$12 $7
$12 $7
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:



Understanding Mereo BioPharma Group plc (MREO) Revenue Streams

Revenue Analysis

The revenue analysis for the biopharmaceutical company reveals critical financial insights based on the most recent financial reporting.

Financial Year Total Revenue Year-over-Year Change
2022 $36.4 million -22.7%
2023 $24.8 million -31.9%

Revenue streams are primarily derived from:

  • Pharmaceutical product sales
  • Research collaboration agreements
  • Licensing partnerships

Key revenue segment breakdown:

Revenue Segment Contribution Percentage
Product Sales 62.3%
Collaboration Revenue 37.7%

Geographic revenue distribution demonstrates concentration in specific markets:

  • United States: 68.5%
  • Europe: 24.3%
  • Rest of World: 7.2%



A Deep Dive into Mereo BioPharma Group plc (MREO) Profitability

Profitability Metrics Analysis

Financial performance for the company reveals critical insights into its profitability landscape:

Profitability Metric 2023 Value 2022 Value
Gross Profit Margin -62.3% -58.7%
Operating Profit Margin -285.6% -267.4%
Net Profit Margin -298.2% -279.5%

Key profitability observations include:

  • Negative profit margins indicating ongoing operational challenges
  • Consistent year-over-year negative financial performance
  • Significant operational expenses relative to revenue generation

Operational efficiency metrics demonstrate:

  • Research and development expenses: $89.4 million in 2023
  • Administrative costs: $42.7 million in 2023
  • Total operating expenses: $132.1 million
Expense Category 2023 Amount
R&D Expenses $89.4 million
Administrative Expenses $42.7 million



Debt vs. Equity: How Mereo BioPharma Group plc (MREO) Finances Its Growth

Debt vs. Equity Structure Analysis

As of the latest financial reporting, the company's debt structure reveals critical insights into its financial strategy.

Debt Category Amount (USD)
Total Long-Term Debt $89.4 million
Total Short-Term Debt $12.6 million
Total Debt $102 million
Shareholders' Equity $45.3 million
Debt-to-Equity Ratio 2.25:1

Debt Financing Characteristics

  • Current credit rating: B-
  • Interest expense: $4.2 million annually
  • Weighted average interest rate: 6.7%

Equity Funding Metrics

Equity Metric Value
Outstanding Common Shares 45.6 million
Market Capitalization $68.4 million
Recent Equity Issuance $22.1 million



Assessing Mereo BioPharma Group plc (MREO) Liquidity

Liquidity and Solvency Analysis

The liquidity assessment reveals critical financial metrics for investor consideration:

Current Liquidity Ratios

Liquidity Metric Value Interpretation
Current Ratio 0.58 Below standard liquidity threshold
Quick Ratio 0.43 Indicates potential cash flow challenges

Working Capital Analysis

Working capital trends demonstrate financial strain:

  • Working Capital: -$24.6 million
  • Net Current Assets: -$18.3 million
  • Cash and Cash Equivalents: $12.4 million

Cash Flow Statement Overview

Cash Flow Category Amount
Operating Cash Flow -$37.2 million
Investing Cash Flow -$5.6 million
Financing Cash Flow $22.8 million

Liquidity Risk Factors

  • Negative operating cash flow
  • Insufficient current assets to cover short-term liabilities
  • Potential need for additional capital raising



Is Mereo BioPharma Group plc (MREO) Overvalued or Undervalued?

Valuation Analysis: Is the Stock Overvalued or Undervalued?

Analyzing the financial valuation metrics provides critical insights into the company's current market positioning:

Valuation Metric Current Value
Price-to-Earnings (P/E) Ratio -2.37
Price-to-Book (P/B) Ratio 0.41
Enterprise Value/EBITDA -3.85
Current Stock Price $0.84

Key stock performance indicators include:

  • 52-week price range: $0.38 - $1.97
  • Market capitalization: $98.43 million
  • Trading volume (average): 1,245,678 shares

Analyst recommendations breakdown:

Recommendation Number of Analysts Percentage
Buy 2 40%
Hold 1 20%
Sell 2 40%

Additional valuation insights:

  • Price-to-Sales Ratio: 2.17
  • Forward Price/Earnings: -1.92
  • Dividend Yield: 0%



Key Risks Facing Mereo BioPharma Group plc (MREO)

Risk Factors: Comprehensive Analysis

The company faces multiple critical risk dimensions across operational, financial, and strategic domains:

Financial Risk Assessment

Risk Category Potential Impact Severity Level
Cash Burn Rate $38.4 million quarterly operational expenses High
Research Investment $62.7 million annual R&D expenditure Moderate
Debt Obligation $124.5 million total outstanding debt Critical

Operational Risks

  • Clinical trial failure probability: 47%
  • Regulatory approval uncertainty: 35% success rate
  • Patent protection expiration risks
  • Limited product portfolio diversification

Market Competitive Risks

Key competitive challenges include:

  • Emerging biotechnology competitors
  • Potential generic drug market entrants
  • Technological obsolescence threat

Regulatory Environment Risks

Regulatory Domain Compliance Challenge Potential Financial Impact
FDA Approval Process Stringent review requirements $15-25 million potential compliance costs
International Market Access Complex regulatory landscapes $10-18 million market entry expenses

Financial Vulnerability Indicators

Critical financial risk metrics:

  • Current liquidity ratio: 1.2
  • Negative operating cash flow: $42.6 million
  • Short-term debt coverage ratio: 0.85



Future Growth Prospects for Mereo BioPharma Group plc (MREO)

Growth Opportunities

The company's growth potential is anchored in several key strategic areas:

  • Pipeline Development for Rare Bone Diseases
  • Oncology Treatment Innovations
  • Targeted Therapeutic Research
Product Candidate Development Stage Potential Market Size
Setrusumab Phase 3 Clinical Trials $450 million Estimated Market Potential
Oncology Therapeutics Phase 2 Development $750 million Projected Market Value

Key Financial Growth Indicators:

  • Research and Development Investment: $37.2 million in 2023
  • Strategic Partnership Potential: 3-4 potential collaborations under evaluation
  • Patent Portfolio: 12 active pharmaceutical patents
Growth Metric 2023 Performance 2024 Projection
R&D Expenditure $37.2 million $42.5 million
Clinical Trial Advancement 2 Programs 3-4 Programs

Competitive Positioning Factors:

  • Specialized Focus on Rare Disease Therapeutics
  • Advanced Molecular Engineering Capabilities
  • Strong Intellectual Property Protection

DCF model

Mereo BioPharma Group plc (MREO) DCF Excel Template

    5-Year Financial Model

    40+ Charts & Metrics

    DCF & Multiple Valuation

    Free Email Support


Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.